The DOI matches its Crossref record.
The Effect of a Gonadotropin-Releasing Hormone Agonist Analog (Nafarelin) on Bone Metabolism
Abstract
The effect on bone metabolism of an agonist analog of GnRH, nafarelin, was studied in 16 premenopausal women, who received 200 micrograms nafarelin/day for 6 months, and 9 premenopausal women, who received 400 micrograms nafarelin/day for 6 months, followed by a 6-month follow-up period. Bone mineral content in the forearm (measured by single photon absorptiometry) and in the spine (measured by dual photon absorptiometry) significantly decreased after 6 months of treatment with 400 micrograms nafarelin, but 6 months after termination of treatment all bone mineral measurements had returned to pretreatment levels. The bone mineral measurements in the 200 micrograms group did not change throughout the study. In both treatment groups the biochemical estimates of bone turnover increased significantly to postmenopausal levels. Withdrawal of treatment resulted in an abrupt decrease in the bone resorption parameters (fasting urinary hydroxyproline to creatinine and calcium to creatinine excretion ratios and serum phosphate), whereas there was a protracted fall in the bone formation parameters (plasma bone Gla protein and serum alkaline phosphatase) 6 months after termination of treatment. Our findings demonstrate that nafarelin in both doses increased biochemical indices of bone turnover, that 400 micrograms/day nafarelin resulted in a significant decrease in bone mineral content, and that these effects were reversible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Gonadotropin-releasing hormone and its analogues
Desforges, J. F., Conn, P. M., & Crowley, W. F. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101103240205 · Cited by 470
PROGRESSIVE OSTEOPOROSIS DURING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER
DANIELL, H. W., DUNN, S. R., FERGUSON, D. W., LOMAS, G., NIAZI, Z., & STRATTE, P. T. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)68000-7 · Cited by 452
Role of Hormones in Pilosebaceous Unit Development
Deplewski, D., & Rosenfield, R. L. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.4.0404 · Cited by 443
Gonadotropin-Releasing Hormone and Its Analogues
Kovacs, P. (2020) · Textbook of Assisted Reproduction · doi:10.1007/978-981-15-2377-9_8 · Cited by 422
Osteoporosis Due to Cancer Treatment: Pathogenesis and Management
Pfeilschifter, J., & Diel, I. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1570 · Cited by 363
Metadata
- Authors
- JOHANSEN, J. S., RIIS, B. J., HASSAGER, C., MOEN, M., JACOBSON, J., & CHRISTIANSEN, C.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1988-10
- Volume
- 67
- Issue
- 4
- Pages
- 701-706
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2129449855
- Cited by
- 189
- References
- 0
- FWCI
- 15.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effect of a Gonadotropin-Releasing Hormone Agonist Analog (Nafarelin) on Bone Metabolism. https://app.cochat.ai/papers/10.1210/jcem-67-4-701
- The paper
- JOHANSEN, J. S., RIIS, B. J., HASSAGER, C., MOEN, M., JACOBSON, J., & CHRISTIANSEN, C. (1988). The Effect of a Gonadotropin-Releasing Hormone Agonist Analog (Nafarelin) on Bone Metabolism. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jcem-67-4-701
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.